GlassScriptPhysician profile
William Kutsche
NPI 1477284602
$496.44
in general payments reported to CMS, 2019-2025
9 companies · $468 in 2025
The $468 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $28.27 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $152.67 | 2025 | Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $83.15 | 2025 | Opsumit, Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $59.71 | 2025 | Zerbaxa, Winrevair |
| Mallinckrodt Hospital Products INC. | $55.03 | 2025 | Terlivaz, Acthar |
| Alexion Pharmaceuticals, INC. | $45.32 | 2025 | Ultomiris |
| Insmed, INC. | $38.34 | 2025 | Brinsupri, Arikayce |
| Acadia Pharmaceuticals INC | $28.27 | 2024 | Nuplazid |
| La Jolla Pharmaceutical Company | $20.29 | 2025 | Zevtera |
| Takeda Pharmaceuticals U.S.A., INC. | $13.66 | 2025 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kutsche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.